Wendi Qian
Overview
Explore the profile of Wendi Qian including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
55
Citations
2853
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Humphrey T, Qian W, Chen-Xu M, Dowling F, Gatley K, Adhikari R, et al.
BMC Infect Dis
. 2025 Feb;
25(1):204.
PMID: 39934669
Purpose: Despite vaccination, many patients remain vulnerable to COVID-19 infection and poorer outcomes, because of underlying health conditions resulting in sub-optimal vaccine responses. This study aims to demonstrate whether intranasal...
2.
Marzolini M, Qian W, Clifton-Hadley L, Patrick P, Warden J, Stevens L, et al.
Br J Haematol
. 2024 Nov;
206(3):876-886.
PMID: 39604791
Traditionally, patients with asymptomatic, advanced-stage follicular lymphoma were managed with a watchful-waiting approach until disease progression. The 'Watch and Wait' Phase-3 randomised international trial examined whether rituximab could delay the...
3.
C Willcocks L, Qian W, Cader R, Gatley K, Siddiqui H, Tabebisong E, et al.
BMC Nephrol
. 2024 Aug;
25(1):253.
PMID: 39112932
Background: Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS) are a spectrum of disease causing the nephrotic syndrome (NS), characterised by proteinuria with debilitating oedema, as well as a...
4.
Abraham J, Pinilla K, Dayimu A, Grybowicz L, Demiris N, Harvey C, et al.
Nature
. 2024 Apr;
629(8014):1142-1148.
PMID: 38588696
PARTNER is a prospective, phase II-III, randomized controlled clinical trial that recruited patients with triple-negative breast cancer, who were germline BRCA1 and BRCA2 wild type. Here we report the results...
5.
Dayimu A, Gupta A, Matin R, Nobes J, Board R, Payne M, et al.
Eur J Cancer
. 2023 Nov;
196:113455.
PMID: 38029480
Background: BRAF+MEK inhibitors extend life expectancy of patients with BRAF mutant advanced melanoma. Acquired resistance limits duration of benefit, but preclinical and case studies suggest intermittent dosing could overcome this...
6.
Watts C, Dayimu A, Matys T, Ashkan K, Price S, Jenkinson M, et al.
J Pers Med
. 2023 Mar;
13(3.
PMID: 36983696
Background: Improving intraoperative accuracy with a validated surgical biomarker is important because identifying high-grade areas within a glioma will aid neurosurgical decision-making and sampling. Methods: We designed a multicentre, prospective...
7.
Humphrey T, Dosanjh D, Hiemstra T, Richter A, Chen-Xu M, Qian W, et al.
Trials
. 2023 Mar;
24(1):185.
PMID: 36915199
Background: Despite the introduction of vaccination, there remains a need for pre-exposure prophylactic agents against SARS-CoV-2. Several patient groups are more vulnerable to SARS-CoV-2 infection by virtue of underlying health...
8.
Dayimu A, Di Lisio L, Anand S, Roca-Carreras I, Qian W, Al-Mohammad A, et al.
Br J Cancer
. 2023 Feb;
128(9):1672-1680.
PMID: 36813867
Background: Chemotherapy for metastatic pancreatic adenocarcinoma (PDAC) offers limited benefits, but survival outcomes vary. Reliable predictive response biomarkers to guide patient management are lacking. Methods: Patient performance status, tumour burden...
9.
Raine T, Pavey H, Qian W, Moran G, Subramanian S, Swaby L, et al.
Gut
. 2022 Jan;
71(4):661-664.
PMID: 35022265
No abstract available.
10.
Ursprung S, Priest A, Zaccagna F, Qian W, Machin A, Stewart G, et al.
PLoS One
. 2021 Oct;
16(10):e0258988.
PMID: 34699525
Purpose: To detect early response to sunitinib treatment in metastatic clear cell renal cancer (mRCC) using multiparametric MRI. Method: Participants with mRCC undergoing pre-surgical sunitinib therapy in the prospective NeoSun...